OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -17.34%163.72M | -49.13%30.58M | 37.37%51.2M | -18.69%57.21M | -18.42%24.73M | 5.84%198.07M | 105.64%60.12M | -37.10%37.27M | 6.50%70.36M | -6.94%30.31M |
Net income from continuing operations | -15.12%16.87M | -109.97%-777K | 16.34%-7.43M | 11.80%16.11M | 36.84%8.97M | -65.51%19.87M | -78.55%7.79M | -420.50%-8.89M | -49.39%14.41M | 219.65%6.55M |
Operating gains losses | -64.93%417K | --2.05M | ---- | ---- | ---- | 104.41%1.19M | --0 | --20K | --29K | 287.76%1.14M |
Depreciation and amortization | -2.39%128.66M | 4.62%33.11M | -3.69%31.82M | -4.89%31.8M | -5.21%31.93M | -0.23%131.81M | -5.27%31.64M | -3.32%33.04M | -1.96%33.44M | 10.71%33.69M |
Other non cash items | -68.98%1.02M | -154.93%-775K | -63.83%476K | 81.92%966K | 790.00%356K | 79.63%3.3M | -2.82%1.41M | 224.14%1.32M | 1,395.12%531K | 110.53%40K |
Change In working capital | -89.23%3.09M | -134.82%-5.56M | 199.83%25.42M | -79.69%3.65M | -49.08%-20.42M | 158.08%28.73M | 191.31%15.96M | -64.03%8.48M | 32,212.50%17.98M | -368.59%-13.7M |
-Change in receivables | 30.10%6.67M | -8.06%6.22M | 147.47%2.83M | -56.61%6.52M | 16.88%-8.89M | 157.51%5.13M | 346.40%6.76M | -315.17%-5.96M | 367.94%15.02M | -40.72%-10.69M |
-Change in payables and accrued expense | 64.85%-2.24M | -129.74%-13.51M | 54.36%9.32M | -118.12%-541K | 126.25%2.5M | -128.31%-6.37M | -110.23%-5.88M | -37.91%6.04M | -59.25%2.99M | -215.46%-9.51M |
-Change in other current assets | -168.65%-18.94M | -143.53%-8.52M | -24.26%5.33M | -107.41%-379K | -272.43%-15.37M | 508.20%27.59M | 351.82%19.57M | 77.40%7.03M | 116.37%5.12M | 22.35%-4.13M |
-Change in other current liabilities | 643.20%17.6M | 328.18%10.25M | 481.07%7.95M | 62.17%-1.94M | -87.38%1.34M | -45.26%2.37M | 46.70%-4.49M | -80.78%1.37M | -24.00%-5.14M | 8.68%10.63M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -17.34%163.72M | -49.13%30.58M | 37.37%51.2M | -18.69%57.21M | -18.42%24.73M | 5.84%198.07M | 105.64%60.12M | -37.10%37.27M | 6.50%70.36M | -6.94%30.31M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 8.85%-108.25M | 53.55%-23.77M | 53.44%-16.46M | -65.03%-35.74M | -205.51%-32.27M | 55.25%-118.75M | -178.07%-51.17M | -117.51%-35.36M | -59.40%-21.66M | 96.49%-10.56M |
Capital expenditure reported | -16.25%-140.55M | 52.52%-24.4M | -32.03%-46.89M | -60.25%-35.84M | -187.36%-33.43M | -71.80%-120.91M | -73.10%-51.4M | -88.50%-35.51M | -55.89%-22.36M | -55.14%-11.63M |
Net other investing changes | 48.68%3.2M | 175.98%632K | 777.33%1.32M | -86.91%92K | 8.40%1.16M | -66.13%2.15M | -75.61%229K | -94.19%150K | -7.13%703K | -48.51%1.07M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 8.85%-108.25M | 53.55%-23.77M | 53.44%-16.46M | -65.03%-35.74M | -205.51%-32.27M | 55.25%-118.75M | -178.07%-51.17M | -117.51%-35.36M | -59.40%-21.66M | 96.49%-10.56M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 39.24%-134.97M | -41.75%-87.86M | 63.88%-15.21M | 81.94%-13.32M | 58.06%-18.58M | -101.85%-222.15M | -56.74%-61.98M | -1,300.23%-42.12M | -7,053.15%-73.75M | 33.36%-44.3M |
Net issuance payments of debt | -54.04%-58.1M | -6,722.21%-55.6M | 86.01%-843K | 97.27%-834K | -118.25%-825K | 45.77%-37.72M | 44.06%-815K | -433.27%-6.03M | -2,858.39%-30.5M | 99.43%-378K |
Net common stock issuance | 87.69%-16.51M | 84.81%-7.65M | 92.50%-1.88M | --0 | 73.91%-6.98M | -375.52%-134.1M | -91.33%-50.36M | -1,233.44%-25.04M | ---31.95M | ---26.75M |
Cash dividends paid | -7.41%-47.92M | -15.88%-12.52M | -13.04%-12.49M | -10.50%-12.49M | 9.04%-10.42M | -281.96%-44.61M | 7.08%-10.8M | ---11.05M | ---11.3M | -21,120.37%-11.46M |
Net other financing activities | -117.58%-12.44M | ---12.09M | --0 | --0 | 93.86%-351K | -811.80%-5.72M | --0 | --0 | --0 | -1,066.73%-5.72M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 39.24%-134.97M | -41.75%-87.86M | 63.88%-15.21M | 81.94%-13.32M | 58.06%-18.58M | -101.85%-222.15M | -56.74%-61.98M | -1,300.23%-42.12M | -7,053.15%-73.75M | 33.36%-44.3M |
Net cash flow | ||||||||||
Beginning cash position | -39.04%223.08M | -18.64%224.63M | -35.16%205.1M | -42.30%196.96M | -39.04%223.08M | -33.98%365.91M | -11.13%276.11M | 16.86%316.31M | 55.71%341.36M | -33.98%365.91M |
Current changes in cash | 44.35%-79.49M | -52.83%-81.05M | 148.56%19.53M | 132.52%8.15M | -6.39%-26.12M | 24.15%-142.84M | -196.00%-53.03M | -200.53%-40.21M | -148.69%-25.05M | 92.67%-24.55M |
End cash Position | -35.64%143.58M | -35.64%143.58M | -18.64%224.63M | -35.16%205.1M | -42.30%196.96M | -39.04%223.08M | -39.04%223.08M | -11.13%276.11M | 16.86%316.31M | 55.71%341.36M |
Free cash flow | -69.98%23.17M | -29.14%6.18M | 144.84%4.31M | -55.47%21.37M | -146.59%-8.7M | -33.91%77.16M | 2,000.00%8.72M | -95.64%1.76M | -7.19%48M | -25.50%18.68M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |